Start Date
September 30, 2007
Primary Completion Date
July 31, 2012
Study Completion Date
July 31, 2012
fludarabine and rituximab
days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
fludarabine, rituximab, pixantrone
days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
Cancer Care Center, Albany
Interlakes Foundation, Inc., Rochester
Northwest Alabama Cancer Center, Muscle Shoals
Hematology Oncology Consultants, Columbus
Heartland Hematology Oncology Associates, Kansas City
Capitol Comprehensive Cancer Care, Jefferson City
Utah Hematology Oncology, P.C., Ogden
Ventura County Hematology Oncology Specialist, Oxnard
Lead Sponsor
CTI BioPharma
INDUSTRY